Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 23%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Incyte Corporation's positive outlook is strongly supported by robust revenue growth driven by increased demand for its leading drug, Jakafi, which experienced a 10% year-over-year increase in paid demand across all indications. The commercial performance of Opzelura, with revenue surpassing expectations at $188 million, underlines the firm’s ability to capitalize on the growing patient demand in dermatology for atopic dermatitis and vitiligo treatments. Furthermore, Incyte's raised fiscal year 2025 guidance to a range of $4.23 billion to $4.32 billion highlights confidence in its oncology portfolio, including Jakafi and other marketed products, indicating strong future financial prospects.

Bears say

Incyte faces significant downside risks primarily due to the erosion of pricing power for its leading drug, Jakafi, which is critical for its sales growth. The firm is also encountering challenges with the performance of its earlier-stage pipeline and potential clinical or regulatory setbacks associated with Jakafi’s combinations. Coupled with competition in the market and concerns regarding safety and efficacy of both marketed products and ongoing clinical trials, these factors contribute to a negative outlook for Incyte's stock.

Incyte (INCY) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 23% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 13 analysts, Incyte (INCY) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.